Brukinsa OverviewZanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It was approved for medical use in the United States in November 2019. Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is administered orally. History Efficacy was evaluated in BGB-3111-206 (NCT03206970), a phase II open-...
Read more Brukinsa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Zanubrutinib
Recent Brukinsa Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 80mg